PE20071092A1 - Composicion farmaceutica que comprende un antagonista de cb1 y un agente antisicotico - Google Patents
Composicion farmaceutica que comprende un antagonista de cb1 y un agente antisicoticoInfo
- Publication number
- PE20071092A1 PE20071092A1 PE2006001558A PE2006001558A PE20071092A1 PE 20071092 A1 PE20071092 A1 PE 20071092A1 PE 2006001558 A PE2006001558 A PE 2006001558A PE 2006001558 A PE2006001558 A PE 2006001558A PE 20071092 A1 PE20071092 A1 PE 20071092A1
- Authority
- PE
- Peru
- Prior art keywords
- pharmaceutical composition
- methyl
- antagonist
- composition including
- chlorophenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UNO O MAS ANTAGONISTAS DEL RECEPTOR CB1 DE FORMULA (I) EN DONDE R ES CR1R2, C=C(R5)SO2R6 O C=C(R7)SO2ALQ; R1 ES H Y R2 ES -C(R8)(R9)(R10), -C(R8)(R11)(R12), ENTRE OTROS; O R1 ES ALQUILO, NH-R15, CN, -S-ALQ-NR16R17-, ENTRE OTROS Y R2 ES -C(R8)(R11)(R12); R3 Y R4 SON INDEPENDIENTEMENTE ALQUILO, CICLOALQUILO, O AROMATICOS TALES COMO FENILO, NAFTILO O INDENILO, OPCIONALEMTE SUSTITUIDOS ENTRE OTROS. SON SELECCIONADOS: (RS)-1-[BIS(4-CLOROFENIL)METIL)]-3-[(3,5-DIFLUOROFENIL)(METILSULFONIL)METIL]AZETIDINA, N-{1-[BIS(4-CLOROFENIL)METIL)]-AZETIDIN-3-IL}-N-(PIRID-3-IL)METILSULFONAMIDA, ENTRE OTROS. EN COMBINACION CON B) UNO O MAS AGENTES ANTISICOTICOS SELECCIONADOS DE OLANZAPINA, CLOZAPINA, HALOPERIDOL, SUCCINATO DE LOXAPINA, ENTRE OTROS. DICHA COMPOSICION ES UTIL PARA TRATAR LOS EFECTOS SECUNDARIOS Y SINTOMAS NEGATIVOS DE LA ESQUIZOFRENIA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74843405P | 2005-12-08 | 2005-12-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20071092A1 true PE20071092A1 (es) | 2007-12-10 |
Family
ID=37964962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006001558A PE20071092A1 (es) | 2005-12-08 | 2006-12-06 | Composicion farmaceutica que comprende un antagonista de cb1 y un agente antisicotico |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20080221078A1 (es) |
| EP (1) | EP1962834A2 (es) |
| JP (1) | JP2009518423A (es) |
| KR (1) | KR20080073737A (es) |
| CN (1) | CN101321523A (es) |
| AR (1) | AR056846A1 (es) |
| AU (1) | AU2006321907A1 (es) |
| BR (1) | BRPI0619541A2 (es) |
| CA (1) | CA2632673A1 (es) |
| CR (1) | CR9957A (es) |
| DO (1) | DOP2006000273A (es) |
| EC (1) | ECSP088505A (es) |
| IL (1) | IL191888A0 (es) |
| MA (1) | MA30090B1 (es) |
| NO (1) | NO20082923L (es) |
| PE (1) | PE20071092A1 (es) |
| RU (1) | RU2008127491A (es) |
| SV (1) | SV2008002929A (es) |
| TN (1) | TNSN08205A1 (es) |
| TW (1) | TW200803839A (es) |
| UY (1) | UY29995A1 (es) |
| WO (1) | WO2007067617A2 (es) |
| ZA (1) | ZA200803924B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200630337A (en) | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| US7906652B2 (en) | 2005-11-28 | 2011-03-15 | Merck Sharp & Dohme Corp. | Heterocycle-substituted 3-alkyl azetidine derivatives |
| WO2007110449A1 (en) * | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
| WO2007118853A1 (en) | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
| TW200812963A (en) | 2006-04-13 | 2008-03-16 | Euro Celtique Sa | Benzenesulfonamide compounds and the use thereof |
| WO2008124118A1 (en) | 2007-04-09 | 2008-10-16 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use therof |
| US8765736B2 (en) | 2007-09-28 | 2014-07-01 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| ES2428326T3 (es) * | 2007-10-04 | 2013-11-07 | Merck Sharp & Dohme Corp. | Derivados de aril sulfona sustituida como bloqueadores de canales de calcio |
| FR2925051B1 (fr) * | 2007-12-18 | 2010-05-21 | Sanofi Aventis | Derives d'azetidines,leur preparation et leur application en therapeutique |
| WO2009106708A2 (fr) * | 2007-12-18 | 2009-09-03 | Sanofi-Aventis | Derives d'azetidines, leur preparation et leur application en therapeutique |
| GB2456183A (en) | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
| WO2010079241A1 (es) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas |
| EP3180335B1 (en) | 2014-08-11 | 2021-05-05 | Angion Biomedica Corporation | Cytochrome p450 inhibitors and uses thereof |
| AU2015374231B2 (en) | 2014-12-31 | 2020-07-23 | Angion Biomedica Corp. | Methods and agents for treating disease |
| FI3504187T3 (fi) | 2016-08-24 | 2025-04-05 | Prilenia Neurotherapeutics Ltd | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6355631B1 (en) * | 2000-03-03 | 2002-03-12 | Aventis Pharma S.A. | Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation |
| US6479479B2 (en) * | 2000-03-03 | 2002-11-12 | Aventis Pharma S.A. | Azetidine derivatives, their preparation and pharmaceutical compositions containing them |
| US6566356B2 (en) * | 2000-03-03 | 2003-05-20 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation |
| WO2005000809A1 (en) * | 2003-06-11 | 2005-01-06 | Merck & Co., Inc. | Substituted 3-alkyl and 3-alkenyl azetidine derivatives |
| EP1663215A1 (en) * | 2003-09-02 | 2006-06-07 | Solvay Pharmaceuticals GmbH | Novel medical use of selective cb1- receptor antagonists |
| WO2006017892A1 (en) * | 2004-08-16 | 2006-02-23 | Northern Sydney And Central Coast Area Health Service | Methods for improving cognitive functioning |
| FR2882931B1 (fr) * | 2005-03-14 | 2007-05-18 | Sanofi Aventis Sa | Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique |
-
2006
- 2006-12-06 DO DO2006000273A patent/DOP2006000273A/es unknown
- 2006-12-06 PE PE2006001558A patent/PE20071092A1/es not_active Application Discontinuation
- 2006-12-07 AU AU2006321907A patent/AU2006321907A1/en not_active Abandoned
- 2006-12-07 JP JP2008544469A patent/JP2009518423A/ja not_active Abandoned
- 2006-12-07 CA CA002632673A patent/CA2632673A1/en not_active Abandoned
- 2006-12-07 CN CNA2006800454370A patent/CN101321523A/zh active Pending
- 2006-12-07 RU RU2008127491/15A patent/RU2008127491A/ru not_active Application Discontinuation
- 2006-12-07 BR BRPI0619541-5A patent/BRPI0619541A2/pt not_active IP Right Cessation
- 2006-12-07 WO PCT/US2006/046547 patent/WO2007067617A2/en active Application Filing
- 2006-12-07 EP EP06839095A patent/EP1962834A2/en not_active Ceased
- 2006-12-07 KR KR1020087013697A patent/KR20080073737A/ko not_active Withdrawn
- 2006-12-07 AR ARP060105411A patent/AR056846A1/es not_active Application Discontinuation
- 2006-12-08 UY UY29995A patent/UY29995A1/es unknown
- 2006-12-08 TW TW095145876A patent/TW200803839A/zh unknown
-
2008
- 2008-05-07 CR CR9957A patent/CR9957A/es not_active Application Discontinuation
- 2008-05-08 TN TNP2008000205A patent/TNSN08205A1/en unknown
- 2008-05-08 ZA ZA200803924A patent/ZA200803924B/xx unknown
- 2008-05-22 US US12/125,285 patent/US20080221078A1/en not_active Abandoned
- 2008-06-02 IL IL191888A patent/IL191888A0/en unknown
- 2008-06-06 SV SV2008002929A patent/SV2008002929A/es not_active Application Discontinuation
- 2008-06-06 EC EC2008008505A patent/ECSP088505A/es unknown
- 2008-06-25 NO NO20082923A patent/NO20082923L/no not_active Application Discontinuation
- 2008-06-26 MA MA31081A patent/MA30090B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20080221078A1 (en) | 2008-09-11 |
| SV2008002929A (es) | 2009-12-02 |
| EP1962834A2 (en) | 2008-09-03 |
| WO2007067617A3 (en) | 2007-11-01 |
| UY29995A1 (es) | 2007-07-31 |
| TNSN08205A1 (en) | 2009-10-30 |
| RU2008127491A (ru) | 2010-01-20 |
| AU2006321907A1 (en) | 2007-06-14 |
| CA2632673A1 (en) | 2007-06-14 |
| WO2007067617A2 (en) | 2007-06-14 |
| DOP2006000273A (es) | 2007-10-15 |
| IL191888A0 (en) | 2009-08-03 |
| ECSP088505A (es) | 2008-08-29 |
| BRPI0619541A2 (pt) | 2011-10-04 |
| MA30090B1 (fr) | 2008-12-01 |
| CN101321523A (zh) | 2008-12-10 |
| TW200803839A (en) | 2008-01-16 |
| KR20080073737A (ko) | 2008-08-11 |
| AR056846A1 (es) | 2007-10-24 |
| NO20082923L (no) | 2008-09-02 |
| ZA200803924B (en) | 2009-10-28 |
| JP2009518423A (ja) | 2009-05-07 |
| CR9957A (es) | 2008-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20071092A1 (es) | Composicion farmaceutica que comprende un antagonista de cb1 y un agente antisicotico | |
| PE20090816A1 (es) | Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3 | |
| NO20080537L (no) | Cycliske anilino-pyridinotriaziner | |
| PE20081374A1 (es) | Combinacion que comprende un agente antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina | |
| PE20010118A1 (es) | Compuestos imidazoles sustituidos como antagonistas de neuropeptido y | |
| CR9214A (es) | 2-fenilindoles como antagonistas del receptor de la prostaglandina d2 | |
| SV2005002099A (es) | " nuevos compuestos " ref. pc 32096a | |
| ATE360631T1 (de) | Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors | |
| ECSP099371A (es) | INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA | |
| PE20081315A1 (es) | Derivados de benzimidazol como antagonistas de vr-1 | |
| ATE360630T1 (de) | Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors | |
| PE20080007A1 (es) | Compuestos derivados de bencimidazolona que tienen actividad en el receptor m1 | |
| CY1110651T1 (el) | Παραγωγα της ν-'(1,5-διφαινυλ-1η- πυραζολ-3-υλ)μεθυλ σουλφοναμιδης με μια συγγενεια για τους υποδοχεις cb1 | |
| ATE507212T1 (de) | Morpholine als 5ht2c-agonisten | |
| NO20090270L (no) | Cinnamoyl-piperazinederivater og deres anvendelse som PAR-I-antagonister | |
| UY29047A1 (es) | Derivados de sulfonamidas, su preparación y su aplicación en terapéutica | |
| PE20091433A1 (es) | Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procedimientos para su preparacion 177 | |
| ATE433454T1 (de) | Pyrazoloä1,5-aüpyrimidine als antagonisten des adenosin-a2a-rezeptors | |
| PE20091431A1 (es) | Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica | |
| GT200900026A (es) | Derivados de 5,6 -bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii | |
| PE20081375A1 (es) | Derivados octahidro-pirrolo[3,4-c]pirrol como antagonistas del receptor ccr5 | |
| PE20070830A1 (es) | Composiciones que comprenden una combinacion de antagonistas ccr5 y de cxcr4 | |
| AR041455A1 (es) | Combinacion de un inhibidor del factor xa y clopidogrel | |
| PE20050350A1 (es) | 2-carbonilamino-6-piperidinaminopiridinas sustituidas y 1-carbonilamino-3-piperidinaminobencenos sustituidos como agonistas de 5-ht1f | |
| PE20070169A1 (es) | Derivados del 4,5-diarilpirrol como antagonistas de receptores cb1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |